Showing results (141-150 of 217) with videos related to
Sort By:
Pageof 22
Annals of Surgery|September 12, 2012
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group studyJed G Nuchtern, Wendy B London, Carol E Barnewolt, et al.European Journal of Cancer (Oxford, England : 1990)|December 6, 2011
Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG projectPaola Angelini, Wendy B London, Susan L Cohn, et al.Pediatric Blood & Cancer|July 22, 2014
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group projectHolly J Meany, Wendy B London, Peter F Ambros, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group projectKieuhoa T Vo, Katherine K Matthay, John Neuhaus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of ageDenah R Taggart, Wendy B London, Mary Lou Schmidt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.Pediatric Blood & Cancer|September 11, 2018
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastomaElizabeth A Sokol, Roger Engelmann, Wenjun Kang, et al.Pediatric Blood & Cancer|November 28, 2018
The challenge of defining "ultra-high-risk" neuroblastomaDaniel A Morgenstern, Rochelle Bagatell, Susan L Cohn, et al.The American Journal of Surgical Pathology|March 19, 2021
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology GroupAsuka Kawano, Florette K Hazard, Bill Chiu, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2013
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology groupGregory A Yanik, Marguerite T Parisi, Barry L Shulkin, et al.Pageof 22